Article
p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2014
Hardwick Nicola R, Carroll Mary, Kaltcheva Teodora, Qian Dajun, Lim Dean, Leong Lucille, Chu Peiguo, Kim Joseph, Chao Joseph, Fakih Marwan, Yen Yun, Espenschied Jonathan, Ellenhorn Joshua D I, Diamond Don J, Chung Vincent
Abstract excerpt
PURPOSE: To conduct a phase I trial of a modified vaccinia Ankara (MVA) vaccine delivering wild-type human p53 (p53MVA) in patients with refractory gastrointestinal cancers. EXPERIMENTAL DESIGN: Three patients were vaccinated with 1.0×10(8) plaque-forming unit (pfu) p53MVA followed by nine patients at 5.6×10(8) pfu. Toxicity was classified using the NCI Common Toxicity Criteria and clinical responses were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.